title: [Characteristics of "Avaxim" hepatitis A vaccine produced by the firm "Pasteur Merrier" (results of field clinical trials)].
abstract: Controlled field clinical trials of Avaxim vaccine from hepatitis A (Pasteur-Merrier-Connot) were carried out in adults and children aged 3-14 years to evaluate its reactogenicity and antigenic properties. The vaccine was weakly reactogenic both in adults and children. A single injection of the vaccine resulted after 1 month in the production of anti-HAV antibodies in 77.4% initially seronegative adults and 94.5% children. In adults the mean geometrical titer of antibodies was 95 mIU/ml and in children 165 mIU/ml, which was 5-8 times higher than the protective titer. These data recommend Avaxim vaccine for practical public health.
authors.forename: M A
authors.initials: MA
authors.lastname: Gorbunov
authors.forename: A V
authors.initials: AV
authors.lastname: Noskova
authors.forename: G A
authors.initials: GA
authors.lastname: El'shina
authors.forename: T A
authors.initials: TA
authors.lastname: Bektimirov
authors.forename: L I
authors.initials: LI
authors.lastname: Pavlova
authors.forename: L A
authors.initials: LA
authors.lastname: Aksenov
authors.forename: A A
authors.initials: AA
authors.lastname: Ivanov
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D002648:Child; D002675:Child, Preschool; D022362:Hepatitis A Vaccines; D006507:Hepatovirus / Q000276:immunology; D006801:Humans; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage* / Q000276:immunology
chemical_list: D000914:Antibodies, Viral; D022362:Hepatitis A Vaccines; D014761:Viral Hepatitis Vaccines